Effects of Temazepam in Patients With Chronic Pulmonary Obstructive Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00245661|
Recruitment Status : Completed
First Posted : October 28, 2005
Last Update Posted : November 2, 2007
The purpose of this study is to evaluate the effects of temazepam during sleep and in daytime on dyspnea, gas exchange and sleep quality in patients with chronic obstructive pulmonary disease.
The study hypothesis is that temazepam does not produce any adverse respiratory effects during sleep in patients with COPD. In contrast, it may result in an beneficiary effect because it positively affects the sleep quality and sleep structure which may result in more alertness and less daytime sleepiness and less dyspnea during the day.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Drug: Temazepam||Phase 3|
Rationale: More than 50% of patients with chronic obstructive pulmonary disease (COPD) have sleep complaints characterised by longer latency to falling asleep, more frequent arousals and awakenings, generalised insomnia and/or excessive daytime sleepiness. Sleep disturbance seems to be more severe with advancing disease and substantially reduces patients' quality of life. The sleep complaints are due to dyspnea, chronic cough, sputum production, hypoxaemia and hypercapnia during the night. One of the available therapies for these patients is the prescription of hypnotics (like benzodiazepines). However, it is thought that in patients with COPD sleep medication may produce adverse respiratory effects due to suppression of the cerebral respiratory drive. In our practice, we never encounter any adverse respiratory effect of an hypnotic in patients with COPD. There have been several trials in COPD patients studying these potentially adverse effects. The results of these studies are inconsistent, relative older hypnotics are used and there are several methodological limitations. Furthermore, in none of these studies transcutaneous PCO2 or PO2 was monitored. Temazepam is nowadays the sedative of first choice in the medical treatment of sleep complaints.
Aim: primary: studying the effects of temazepam on the respiratory function during daytime and at night in patients with severe COPD. Secondary: studying the effects of temazepam on the sleep quality and sleep structure and on the objective and subjective sleepiness during daytime and at night in patients with COPD.
Study design: double blind, placebo-controlled, cross-over randomised clinical trial.
Treatment: 10 mg temazepam or placebo during seven consecutive nights.
Endpoints: Primary: difference in PtcCO2, PtcO2 and oxygen saturation during sleep after 1 week temazepam compared to placebo. Secondary: Respiratory Disturbance Index, Desaturation Index and Hypercapnic Ventilatory Response, percentage REM/nREM-sleep and total effective sleep time, Multiple Sleep Latency Test and the Epworth Sleeping Score.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||14 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Effects of Temazepam on Dyspnea, Gas Exchange and Sleep Quality in Chronic Obstructive Pulmonary Disease.|
|Study Start Date :||October 2005|
|Study Completion Date :||August 2007|
- transcutaneous PCO2
- transcutaneous PO2
- Oxygen saturation
- Respiratory Disturbance Index
- Desaturation Index
- arterial PO2
- arterial PCO2
- Hypercapnic Ventilatory Response
- total sleeping time
- sleep latency
- percentage REM- and nREM-sleep of total sleep time
- number of arousals
- number of apneas during sleep
- number of hypopneas during sleep
- Epworth Sleeping Score
- Dyspnea Visual Analog Score
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245661
|Arnhem, Gelderland, Netherlands, 6800 TA|
|Principal Investigator:||Gerben Stege, MD||Rijnstate Hospital|
|Study Director:||Peter J de Bruijn, MD||Rijnstate Hospital|
|Study Director:||Richard PN Dekhuijzen, Prof. PhD MD||UMC St. Radboud|
|Study Director:||Frank JJ van den Elshout, PhD MD||Rijnstate Hospital|
|Study Director:||Yvonne F Heijdra, PhD MD||UMC St. Radboud|
|Study Director:||Marjo JT van de Ven, PhD MD||Rijnstate Hospital|
|Study Chair:||Petra JE Vos, PhD MD||Rijnstate Hospital|